Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.
Eli Lilly and Immunocore have agreed to collaborate on R&D into novel T-cell-based cancer therapies ... If Immunocore does not exercise its option, it will be entitled to potential future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback